Inventurus Knowledge Solutions Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 24 May 2026 | IT - Services | Market Cap: ₹32.2K Cr
TruBridge's EHR business has a mature market with limited growth potential in market share, currently holding about 35% in rural EHR segment. Revenue growth: Management targets growth faster than the outsourced TAM growth rate of 12%, signaling market share gains.
From Inventurus Knowledge Solutions Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,786
Market Cap
₹32.2K Cr
P/E Ratio
42.2
How does Inventurus Knowledge Solutions Ltd rank in IT - Services?
Compare Inventurus Knowledge Solutions Ltd against every IT - Services company this quarter on revenue, margins and earnings-call signals.
Inventurus Knowledge Solutions Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹858 Cr, net profit ₹206 Cr.
Full financials →📊 Revenue & Sales Performance
- →TruBridge's EHR business has a mature market with limited growth potential in market share, currently holding about 35% in rural EHR segment.
- →Focus will be on modernizing TruBridge’s EHR and integrating it with the system of action to unlock growth via cross-selling.
- →Only ~250 out of 700 TruBridge EHR customers use the RCM system; significant room to cross-sell RCM and other system features into remaining customer base.
- →Growth vectors lie in increasing adoption of additional features across the existing TruBridge EHR install base rather than expanding EHR market share aggressively.
- →The overall market is large ($260 billion TAM with $35 billion outsourced TAM growing at 12%), and IKS aims to grow faster than 12% annually to gain market share.
- →Customer growth strategies include expanding volume through more physicians, increased feature usage, and client concentration management.
- →Use of AI and platform integration expected to drive efficiency and create competitive differentiation, supporting revenue growth.
📈 Profitability & Margins
- →Revenue growth: Management targets growth faster than the outsourced TAM growth rate of 12%, signaling market share gains.
- →EBITDA growth: The company showed 38% YoY EBITDA growth with a healthy margin (~34%), indicating operating leverage benefits.
- →PAT growth: Profit after tax increased 48% YoY, benefiting from lowering interest costs due to debt repayment.
- →EPS growth: Earnings per share grew 43% YoY, reflecting strong profitability and shareholder value creation.
- →Operating cash flow: Operating cash flow nearly doubled YoY with free cash flow at 85% of PAT, supporting sustainable growth.
- →Platform strategy: Focus on expanding a platform system of action with AI integration is expected to drive future margin expansion.
- →TruBridge acquisition: Modernizing EHR and cross-selling system of action features expected to add moderate growth vector beyond core physician group market.
- →Caution on pricing: Some feature pricing could face deflation due to automation; however, platform pricing mitigates commoditization risk.
- →Overall: Expect continued strong earnings growth driven by cross-selling, AI-enabled efficiency, and expanding high-value client relationships.
🏗️ Capital Expenditure Plans
- →No specific mention of large current or future capital expenditure (capex) or strategic investments except for transformative acquisitions like TruBridge.
- →The company is focused on small tuck-in acquisitions and AI capability enhancements, like the deal with ARAI, which are smaller in nature but accelerate AI competency.
- →TruBridge acquisition is highlighted as a rare transformative deal; no anticipation of similar large-scale acquisitions soon due to financial discipline (3x leverage post-close).
- →Emphasis on internal growth and deleveraging balance sheet rather than raising equity or pursuing more large acquisitions.
- →Continued investments in proprietary technology, AI engineering (550 technology employees), and sales & marketing are ongoing, supporting platform development without specific capex figures.
- →Overall, the strategy centers on organic growth, platform modernization, and selective small-scale acquisitions rather than heavy capital investments.
💰 Fundraising & Capital Structure
- →No immediate plans for transformative acquisitions like TruBridge in the near future.
- →The TruBridge acquisition is expected to result in approximately 3x leverage of EBITDA at close.
- →The company intends to focus on deleveraging the balance sheet through internal accruals and strong cash flows post-TruBridge acquisition.
- →Discipline will be maintained to avoid over-leveraging or unnecessary dilution of shareholder equity by raising equity.
- →The company remains open to small, highly accretive tuck-in type acquisitions but not large transformative deals.
- →Overall, no new large debt or equity fundraising is anticipated soon; focus is on managing existing leverage and selective small-scale acquisitions.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Inventurus Knowledge Solutions Ltd Q4 FY26 results?
TruBridge's EHR business has a mature market with limited growth potential in market share, currently holding about 35% in rural EHR segment. Revenue growth: Management targets growth faster than the outsourced TAM growth rate of 12%, signaling market share gains.
What is Inventurus Knowledge Solutions Ltd share price analysis?
Inventurus Knowledge Solutions Ltd currently shows a neutral. The stock trades at a P/E of 42.2 with a market cap of ₹32,233 Cr. Investors should review the full earnings analysis for detailed insights.
Is Inventurus Knowledge Solutions Ltd planning capital expenditure?
No specific mention of large current or future capital expenditure (capex) or strategic investments except for transformative acquisitions like TruBridge.
Keep Inventurus Knowledge Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.